Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

    NEXT STORY
    Nurse Call Systems Market to Reach USD 2.79 Billion by 2026; Rising Incidence of Chronic Diseases to Propel Market, says Fortune Business Insights
    PREV STORY
    Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Great Basin Scientific Granted U.S. Patent for PCR Amplification Suppressor

    SALT LAKE CITY, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), ...

    author_avatar
    NASDAQ Market News

    TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

    PRESS RELEASE TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell ...

    author_avatar
    NASDAQ Market News

    ABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

    REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 26 March 2018 - Ablynx [Euronext Brussels ...

    author_avatar
    NASDAQ Market News